by | Oct 9, 2024 | Uncategorized
Source: CureToday articles Ninlaro, Thalomid and dexamethasone followed by Ninlarlo maintenance may improve durability of response in myeloma after stem cell transplantation relapse. Read More
by | Oct 5, 2024 | Uncategorized
Source: CureToday articles The biologics license application seeks potential approval of a Darzalex Faspro-based regimen for newly diagnosed multiple myeloma ineligible for transplant. Read More
by | Oct 3, 2024 | Uncategorized
Source: CureToday articles Reflecting on the pain I experienced before my diagnosis of multiple myeloma, I realized how important it was to pay attention to the related symptoms. Read More
by | Oct 2, 2024 | Uncategorized
The timing with which patients with newly diagnosed multiple myeloma began treatment with oral antimyeloma medications varied greatly by age and race, according to retrospective study results.Black individuals and older adults appeared significantly less likely to...
by | Sep 20, 2024 | Uncategorized
The FDA approved isatuximab-irfc in combination with bortezomib, lenalidomide and dexamethasone for treatment of certain adults with multiple myeloma.The indication applies to adults with newly diagnosed disease who are not eligible for autologous stem cell...
by | Sep 20, 2024 | Uncategorized
Source: CureToday articles The Food and Drug Administration has approved Sarclisa as a first-line treatment for patients with multiple myeloma who are ineligible for autologous stem cell transplant. Read More
